Audrey’s Life Science Meeting Picks for Nov. – Dec. 2009
(Dec. 5th Edition)
***************************************************************
Palo Alto AWIS, Monday Evening, Dec 7, 2009
Event: “Winter Networking Social
Date and Time: Monday, Dec. 7, 2009, Time: 7 - 9 pm
7:00-7:30 pm Light supper
7:30-9:00 pm Networking activities
Place: PARC Auditorium, 3333 Coyote Hill Road, Palo Alto, CA
Cost: Members pay $5 and non-members pay $10 to offset the cost of food.
Event Description
WHO AWIS Members & Friends • Scientists • Engineers • Educators • Students
Researchers • Writers • Business Representatives • Men too!
WHAT A reception with great food, fun games, and active networking activities
WHY Meet new people. Expand your social and professional networks.
Have fun!
RSVP Online http://www.acteva.com/go/pa-awis
Welcome!! You don’t need to be a member to attend. All scientists, students, and their
friends are
welcome.
************************************************************
Bay Bio Medical Device Breakfast, Tuesday Morning, Dec. 8, 2009 (Event
postponed to Feb. 9, 2010 due to low enrollment)
Topic: “Company Valuation for M&A”
Moderator: Mark Weeks, Partner, Cooley Godward Kronish LLP
Panel Speakers:
Jason Yip, Principal, Montgomery & Co., LLC
Jeffrey Gold, Venture Partner, Longitude Capital, Former CEO, CryoVascular Systems
Time and Date: Dec. 8, 2009, 8:00 -10:00 am
Location: Cooley Godward Kronish LLP, Palo Alto Campus, 3175 Hanover Street, Palo
Alto, CA 94304
Early Bird Registration through Dec. 4:
$10.00 - BayBio & MDMA Members, Bio2Device and Bio-X Affiliates
$20.00 - Non-Members
On-Site Registration, Dec. 8:
$20.00 - BayBio & MDMA Members, Bio2Device and Bio-X Affiliates
$40.00 - Non-Members
Register at http://www.acteva.com/booking.cfm?bevaid=192797
Topic Description
The valuation of a medical device company for merger or acquisition is not an exact
science. Some of the many variables to be taken into consideration include the
company’s management, market share, prospects for growth, and potential market size.
1
2/18/2016
Tangible and intangible assets and financial track record will be evaluated, as well as the
company's reputation in the business community. The motivation and goals of key
players also come into play, and current market conditions and timing are factors. A
panel of industry veterans will explore the valuation process for medical device
companies, discuss case studies and provide practical answers to help you increase your
company’s valuation.
*********************************************************************
Recap’s Free, Live Webinar, Tuesday Morning, Dec. 8, 2009
Topic: “2009 Biopharma Financings Year-In-Review for Insights into 2010 Dealmaking”
Date and Time: December 8, 2009, 10:00-11:00 AM Pacific / 1:00-2:00 PM Eastern
2009 Year-in-Review
Register for Recap’s free, live webinar on December 8th. Join us for a review of the
venture, corporate, and public equity financings from 2009 to glean insights on what to
expect in 2010 dealmaking. We’ll explore:
 An overview of how many venture-to-biotech deals were done and other biotech
venture statistics highlights from 2009.
 Thoughts on how venture funds may position their biopharma portfolios for a
possible liquidity event.
 What we can learn from prior funding cycles.
Who should attend:
 Biopharma corporate executives
 VCs and investment banks
 Business development
 CFOs and financial executives
 Legal
Register to attend today!
This free webinar will be broadcast live on December 8, 2009, 10:00-11:00 AM Pacific /
1:00-2:00 PM Eastern. Event reminders along with the webinar details (call-in phone
number and link to the online presentation) will be sent to you prior to the event date.
Previous Webinars
Register to View Previous Webinars
**********************************************************************
Bio2Device Group, Tuesday Evening, Dec. 8, 2009
Topic: “Science + Commercialization = Valuation. Building a Commercial Story that
Resonates with Prospective Partners.”
Speaker: Harris Kaplan, President and Chief Executive Officer, Healogix
Date and Time: Tuesday, Dec.. 8, 2009, 6:00 – 9:00 pm
Location: Location: TIPS Group Law Offices , 1000 Elwell Court, Palo Alto, CA 94303
Cost: Fee for light dinner with range depending on timing of registration:
MUST REGISTER THRU Google CHECKOUT on the B2DG Website
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
Topic Description
The biotech IPO window has been closed for some time now and is unlikely to reopen
anytime soon. As a result, biotech executives are increasingly reliant on a big pharma or
2
2/18/2016
big biotech to provide the capital needed to continue to develop promising new
compounds and the competition for pharma or biotech dollars is intense. The larger
companies differ significantly from financial investors. They are at least as concerned
about how the product will perform in the market post launch as they are about the
science. Thus, it is as important for a biotech executive understand the
commercialization opportunity and to make that story come to life for an executive.
Think venture capital but without a requirement that “monies have to be put to work.”
A biotech executive has to make one of these larger companies want to do a deal with
your company.
This talk will focus on how biotech executives go about building a robust commercial
story – what elements need to be included in that story and how to position compounds
so they are very attractive to pharma and big biotech scientists and business
development executives. Most biotech deals get one opportunity to present their
technology and/or product. This talk will help company executives make that one time
count.
Speaker Bio
Harris Kaplan is currently President and Chief Executive Officer of Healogix, a
consultancy formed in late 2005 that advises companies on how to create and maximize
the value of new products in development.
Harris has extensive experience in the pharmaceutical industry both on the client and
consulting side of the business and has worked on the introduction of more than 75 new
products including Lipitor, Crestor, Nexium, Rituxan, and Herceptin.
Harris co-founded Migliara-Kaplan Associates which became the world’s largest custom
marketing research company serving 19 of the top 20 pharmaceutical companies.
Migliara-Kaplan Associates specialized in helping companies identify new product
opportunities and then maximizing the commercial potential of new products in
development. Migliara-Kaplan was acquired by NFO in 1996 and is now part of TNS
Healthcare. Harris was also cofounder of Cozint Interactive which was acquired by GFK,
the German based research company. Harris serves as an advisor to several venture
capital funds and is on the Board of Directors of Informedix and the Kernan Orthopedic
Hospital.
***********************************************************
East Bay Association of Women in Science (ebAWIS), Tuesday Evening, Dec. 8,
2009
Topic: *December Networking Social*
Date and Time: Tuesday, December 8, 2009, 6:30 – 8:00 PM
Location:: Jupiter Bar
Location: 2181 Shattuck Ave., Berkeley, CA 94704
Cost: Free (cash bar)*
Please join us at Berkeley's popular microbrew pub, Jupiter, for an informal
gathering of AWIS members and friends!
Directions: http://www.jupiterbeer.com/jupiter/info.htm*
Everyone is welcome, including non-scientists and men. If you are not an
AWIS member yet, please join us!
************************************************************
Tri-Valley IMC Consultants Forum Breakfast, Wednesday Morning, Dec. 9, 2009
3
2/18/2016
Topic: "Planning for a Successful 2010" presented by a panel of our own members.
Date and Time: December 9, 7:15 - 9:00 a.m.
Location: San Ramon Marriott Hotel
Cost: $20 in advance ($25 at the door) includes breakfast.
Register at http://www.brownpapertickets.com/event/90377
Who Should Attend?
• Consultants eager to enhance their practices with new tools and professional
development
• Experienced professionals planning to launch a second career in consulting
• Independent management consultants looking to collaborate with other like minded
professionals
• Business advisors wondering if certification as a management consultant (CMC©)
would add credibility to their practices
If you fit ANY of the above, you owe it to yourself to attend this meeting. Space is
Limited.
http://www.brownpapertickets.com/event/90377
For more information about Tri-Valley Consult ants Forum or the December meeting, go
to the Tri-Valley Consultants Forum Linked-In Group site at
http://www.linkedin.com/groups?gid=2025389&trk=myg_ugrp_ovr
or e-mail TriValleyIMCConsultantsForum@gmail.com
This group/forum is for professional consultants based in the 580/680 corridor, from
Martinez to Hayward, Livermore to Castro Valley. The objective is to create an
atmosphere of partnership, comraderie and the exchange of best practices. The group
will conduct monthly meetings with presenters speaking to topics for consultants starting
in September '09 in the San Ramon, CA area.
*************************************
IEEE, Special Meeting for Unemployed IEEE Members, Wednesday Mid-Day,
Dec. 9, 2010
Topic: “The Professional Job Hunt: Practical Ideas Using LinkedIn and Other Tools”
Speaker and Panel
John Swan, one of the organizers of PACE's new "Engineers in Transition" Task Force;
plus a panel with backgrounds in recruiting, HR, and/or career counseling in the hightech industry.
Date and Time: Wednesday, December 9, 2009, 11:30am ~ Noon: Networking/Pizza
Noon ~ 2:00pm Presentation, panel and discussions
Location: UC-Santa Cruz Extension, 2505 Augustine Drive, Suite 100, Santa
Clara
Registration - - Registration - - LIMITED SEATING – Register Now!
Please register by Monday, Dec. 7th, using our DoubleKnot Registration
IEEE Members – Free
Nonmembers – $10
Visit the PACE Web page for complete information on this event. Come ready
to take notes!
***************************************************************
French American Chamber of Commerce, Wednesday Evening, Dec. 9, 2009
Topic: “A Window into French Life Science Companies”
4
2/18/2016
Panel
François Miceli, CEO, Imaxio
Nicolas Pasqual, CEO and co-founder, ImmunID Technologies
Christelle Dagoneau, Business Development Director, PX Therapeutics
Moderator
Frederick Dorey, Special Counsel, Cooley Godward Kronish LLP
Wednesday December 9th 6:00PM - 8:30PM
Location: Cooley Godward Kronish LLP - Palo Alto - Get directions
Register here
Members $20
Non Members $25
At the door $35
Topic Description
''Lyonbiopole'', the French center of excellence in vaccines and diagnostics, is coming to
the Bay Area. Meet French life sciences executives from Lyon, the capital of immunology
and bioproduction in France and Europe and learn about their innovative approaches to
immunomonitoring, vaccine therapy and biomanufacturing. Imaxio is a
biopharmaceutical company specializing in oncology and infectious diseases, for which
the company develops and commercializes diagnostic and therapeutic products.
ImmunID offers innovative immunomonitoring & diagnostic solutions to characterize
immune dysfunction and analyzes the impact of immunotherapy on Immune Repertoire.
PX Therapeutics provides integrated bio therapeutics and recombinant vaccines
development and manufacturing contract services. Join us for an evening of unique
insights into 3 French life sciences companies.
Panel Speaker Bios
François Miceli, CEO, Imaxio
Imaxio is a biopharmaceutical company specializing in the fields of oncology and
infectious diseases, for which the company develops and commercializes diagnostic and
therapeutic products. As for example, company markets throughout France a vaccine
against leptospirosis. In collaboration with the University of Oxford, through a Grand
Challenges in Global Health grant to the Jenner Institute, novel viral vector vaccines
against neglected diseases are being developed which incorporate Imaxio's proprietary
aXentTM adjuvant. (Industrial partnership agreements have also been signed for the
adjuvant).
Nicolas Pasqual, CEO and co-founder, ImmunID Technologies
Thanks to its original concept of "Immune Weather Forecast" ImmunID offers innovative
immunomonitoring & biomarker diagnostic solutions to characterize immune dysfunction
and analyse the impact of immunotherapy on Immune Repertoire. ImmunID solutions
are used from research to clinical validation to measure efficacy and toxicity risk of
molecules such as Monoclonal antibodies (anti-CD20...), Interleukins (IL2, IL7...), or
vaccines (prophylactic or therapeutic). ImmunID personalized medicine solutions are
used to diagnose certain pathologies such as Lymphoma and Leukemia, and to monitor
immunodeficiency and follow up disease progression and immunomodulators efficacy.
Pathologies mainly concerned are blood cancers, infectious diseases, cancers,
autoimmune diseases.
Christelle Dagoneau, Business Development Director, PX Therapeutics
The company provides integrated bio therapeutics and recombinant vaccines
development and manufacturing contract services. They are organized around three
5
2/18/2016
integrated service platforms : recombinant protein R&D, monoclonal antibody
development and cGMP manufacturing. ). They gained substantial experience in the
production of challenging proteins and developed trusted relationships with more than
140 pharmaceutical, biotech and academic partners worldwide, as for example : Merial,
Sanofi Pasteur, Biomérieux, BD, Tibotec, GSK, Pfizer, Galderma, Stallergenes, etc.
Frederick Dorey, Special Counsel, Cooley Godward Kronish LLP
Fred Dorey is a special counsel in the Life Sciences practice group of the Cooley
Godward Kronish Business department and is active in the Clean Technologies practice
group. He joined the Firm in 1997 and is resident in both the Palo Alto and San Francisco
offices.
**********************************************************
BioMEDevice Expo Hall Admission, Dec. 9-10, 2009
Event: "BIOMEDevice San Jose 2009"
Datss: Wednesday and Thursday, Dec. 9-10, 2009
Location: San Jose McEnery Convention Center, San Jose, CA
We would like to extend our offer of complimentary expo hall admission to your
colleagues. Simply forward this message to them so that they can register online and
save the $45 on-site fee. Register for free admission at
https://www.compusystems.com/servlet/ar?evt_uid=741&PriorityCode=EH
CANON COMMUNICATIONS LLC " 11444 W. Olympic Blvd. " Los Angeles, CA 90064 "
USA
**********************************************************
Bio2Device Group, Tuesday Morning, Dec. 15, 2009
Event: Special Holiday Networking Event
Date and Time: Tuesday, Dec. 15, 8:30 am
Location: TIPS Facility (our normal Evening Meeting Facility), 1000 Newell Rd., Palo Alto
There is no meeting at the Sunnyvale City Chambers for this last meeting of 2009.
Please preregister for the event. There will be no charge for the event, but please log
into the
Google Checkout and register for the morning Holiday Networking event.
Your registering will allow B2DG to know ahead of time how many members and
guests to expect (need to know how much food to buy- can't fully celebrate
without food and drink). There will be a limit of total attendees of 85.
***********************************************************
GABA, Tuesday Lunchtime, Dec. 15, 2009
Topic: “New Solutions for the Medical Arena - The Fraunhofer Heinrich Hertz Institute
and Its Latest Developments”
Speakers:
 Prof. Hans-Joachim Grallert, Managing Director Heinrich Hertz Institute
 Ulrich Leiner, Dept. Head Interactive Media, Heinrich Hertz Institute
 Juergen Rurainsky, Dept. Image Processing, Heinrich Hertz Institute
Date and Time: Tuesday, Dec 15, 2009, 11:30 AM - 02:00 PM
6
2/18/2016
11:30 - 12:00 pm Registration / Networking Reception
12:00 - 12:20 pm Welcome and Intro Heinrich Hertz Institute
12:20 - 12:50 pm 3-D in Theory und Practice Touchless Applications for Medical
Purposes
12:50 - 01:20 pm Image Processing and its Contributions for the Medical Arena
01:20 - 01:30 pm Discussion of the requirements and needs from the medical
perspective
followed by a Guided Tour of the 2-D-Displays, Gesture Interface and
Complimentary lunch included.
Location: Mission Bay Conference Center at UCSF, 1675 Owens Street, San Francisco,
CA
Early registration is recommended since space is limited. This event is free of charge
with online registration. Register at
https://s08.123signup.com/servlet/SignUp?PG=1532265182300&P=1532265191159838
900&Info=
Topic Description
The cost of healthcare can be reduced through the use of more efficient medical
visualization, image processing and diagnostic tools. The Fraunhofer Heinrich Hertz
Institute, a leading international applied research institute, has made groundbreaking
developments in these areas.
Come and join us for an insight into these exciting and efficient technologies and a Q&A
session following the presentation.
New Displays and Interfaces: Using the virtual reality of 3-D co-operation spaces allows
for better orientation and teamwork, and a faster analysis or response to a given
situation. The speakers will show different 3-D approaches in theory and practice and
demonstrate touchless control and applications for medical purposes.
Image Processing and Diagnostics: To analyze and categorize the huge amount of data
provided by the new imaging technologies is a great challenge. Fraunhofer developed
solutions for creating, archiving and processing great amounts of visual data such as
images derived from electronic endoscopy, wireless sensor networks, auto-stereoscopic
3-D displays, picture and video retrieval systems, as well as new ways to find and
compare similar disease patterns.
See the following exhibits:
 New 3-D Displays: Experience 3-D without wearing glasses
 iPointPresenter: Touchless gesture controll
Connecting the different areas of competence creates a great variety of novel
approaches and solutions with significant economic transfer potential. To mention a few:
 autostereoscopic 3D displays for medical applications such as diagnosis and
education
 touchless interaction of devices and systems in a sterile environment; the
optimisation of the workflow during surgery under sterile conditions requires the
application of new interactive technologies
 electronic endoscopy; with the help of intelligent coding procedures, the signal
processing of the HD signal at source can be carried out in an energy-efficient
manner and free of loss
 sensor networks via air (e.g. generating/transmitting vital-data)
 video-retrival and –analysis for finding and comparing similar disease patterns to
support diagnosis verification
7
2/18/2016
********************************************************
BioScience Forum, Wednesday Evening, Dec. 16, 2009
Topic: "The Discovery of Novel Boron-Containing Antimicrobial Agents”
Speaker: Jake Plattner, Ph.D., Senior Vice President, Research, Anacor Pharmaceuticals
Date and Time: Wednesday, Dec. 16, 2009
Time: 6pm Networking, 7pm Dinner, 8pm Presentation
Location: Location: The Clarion Hotel, 401 East Millbrae Ave., Millbrae, CA
Registration is $50 ($35 for full-time students). Parking $4. On-site registration: add
$10 to pre-registered price. Register online at www.acteva.com/go/biosf before
Monday, December 14th, 2009 at 11:55pm.
Or you may pay with a check made out to "BioScience Forum" and sent to
BioScience Forum
1442A Walnut St. #308
Berkeley CA 94709-1405
Please do not mail checks later than Thursday, December 10th, 2009
Registration is $50 ($35 for full-time students). Parking $3. On-site registration: add
$10 to pre-registered price.
(We can only accept cash or checks at the door. There is an ATM machine in the hotel
lobby.)
Topic Description
Anacor was founded in 2002 based on technology created by Dr. Lucy Shapiro, a
Microbial Geneticist at Stanford University, and Dr. Stephen Benkovic, a Bio-Organic
Chemist at Pennsylvania State University. The technology was based on inhibition of
specific bacterial targets using unique boron-containing compounds. Previous attempts
by drug researchers to incorporate boron into drug molecules focused on boronic acids,
which were designed primarily as serine protease inhibitors. These compounds, while
being potent enzyme inhibitors, were limited in their development by their poor druglike properties and high chemical reactivity. At Anacor, we have overcome these
limitations and created a boron-containing compound collection that combines the Porbital reactivity of the boron with chemical stability and selectivity characteristics so
that the resulting compounds have intrinsic drug-like properties. The compounds retain
their ability to react with active site functional groups in proteins, but do so in a very
selective manner. The Anacor compound collection, by the unique incorporation of a
boron atom into the chemical structures, differs significantly from virtually all existing
compound libraries and therefore represents a new and rich source of chemical matter
for screening against biological targets (cells and/or proteins).
The drug-like properties and chemical diversity of Anacor’s boron compound collection
has provided a remarkably high level of success in screening against microbial and
parasite assays. Dr. Plattner will review characteristics of Anacor’s boron compounds and
describe several programs that have produced drug candidates and/or clinical
compounds.
Speaker Biography
Jake Plattner, Ph.D., joined Anacor as Senior Vice President of R&D in February, 2004.
Dr. Plattner received his B.S. degree from the University of Illinois and went on to
8
2/18/2016
complete his Ph.D. degree in organic chemistry from the University of California,
Berkeley in 1972. Dr. Plattner joined Pfizer, Inc. in 1973 as a research chemist working
in the areas of analgesics, antipsychotics and prostaglandins. In 1977, Dr. Plattner
joined Abbott Laboratories as chemistry Group Leader in the Diagnostics Division. After
several years he transferred to the Pharmaceutical Research Division and, while working
on diuretics and antihypertensives, progressed through increasing levels of responsibility
to become Vice President of Anti-infective Research in 1992. In this capacity, he led fully
integrated project teams focusing on antibacterials, antifungals, natural products,
anticancer agents and antivirals. In the area of antivirals, Dr. Plattner initiated the antiHIV discovery research program at Abbott and supervised the research effort that led to
two commercial HIV protease inhibitors. In 1998, Dr. Plattner joined Chiron Corporation
as Vice President of Small Molecule Discovery Research and managed programs that led
to several drugs now in clinical trials for cancer (now with Novartis).
Dr. Plattner has served on the Division of Medicinal Chemistry's Award Committee and
the Long Range Planning Committee (1994-1996). He has organized a number of
symposia at major meetings, including the National Medicinal Chemistry Symposium,
the Interscience Conference on Antimicrobial Agents and Chemotherapy and the
Medicinal Chemistry Gordon Research Conference. In 1994, he also served as Chairman
of the Gordon Research on Medicinal Chemistry. He served as a section editor for Annual
Reports in Medicinal Chemistry for 12 years. He has also served on the editorial board
for Burger’s Medicinal Chemistry, is a co-editor for Volume 7 of Comprehensive Medicinal
Chemistry II and is currently a co-editor of Current Opinion in Investigational Drugs. He
is author and co-author of over 150 publications and has contributed a number of invited
papers and talks.
*********************************************************************
Free UCSC Ext. Program Overview, Monday Evening, Jan. 11, 2010
Event: Program Overview for Biotechnology, Bioinformatics and Bioscience Business and
Marketing
Date and Time: Monday, Jan. 11, 2010, 6–8:30 pm
Location: UCSC Extension Classroom, 2505 Augustine Drive, Santa Clara
No fee, but enrollment required.
16649-010 (use course-section number to enroll)
Register at http://www.ucsc-extension.edu/biosciences--click on enroll now
Descripton
Are you interested in learning about the Bioinformatics, Biotechnology, and Bioscience
Business and Marketing certificate programs, and about careers in these fields?
This free information session provides an opportunity to meet instructors and other
students, learn about program prerequisites, course content and program requirements,
andsee how these programs can help you advance your current career or break into a
new field.
*********************************************************************
Free UCSC Ext. Program Overview, Monday Evening, Jan. 13, 2010
Event: Clinical Trials and Regulatory Affairs Program Presentation
Date and Time: Wednesday, Jan. 13, 2010, 6–8:30 pm
Location: UCSC Extension Classroom, 2505 Augustine Drive, Santa Clara
No fee, but enrollment required.
16650-010 (use course-section number to enroll)
Register at http://www.ucsc-extension.edu/biosciences--click on enroll now
9
2/18/2016
Descripton
Are you interested in learning about the Clinical Trials and Regulatory Affairs certificate
programs, and about careers in these fields? This special information session provides
an opportunity to meet instructors and other students, learn about program
prerequisites, program philosophy, course content and program requirements, and gain
insights into careers in clinical research and regulatory affairs.
**********************************************************************
FountainBlue Life Science Entrepreneur’s Forum, Monday Evening, Jan. 25,
2010
Topic: Life Science Angel Investor's Panel: Trends for 2010
This month's panel will feature:




Facilitator Conor Moore, Partner, KPMG
Panelist Anne DeGheest, Founder and Managing Director, MedStars, Strategic
Advisor at PolyRemedy, Inc
Panelist Don Ross, Member, Life Science Angels and Sand Hill Angels
Panelist Michael Weickert, President and CEO, S.E.A. Medical Systems, Inc.,
Member, Life Science Angels, Venture Partner, Kranenburg Fund
Another Angel Investor to be confirmed
Date & Time: Monday, January 25 from 5:30 - 7:30 p.m.
Location: KPMG, 500 E. Middlefield Road, Mountain View
Coordinate a Carpool by visiting http://search.zoompool.com/index.php?eventid=800.
Cost: $21 members, $32 partners, $42 general
On-Site Registration is $42 for members, $52 for nonmembers, or $104 for FountainBlue
Ongoing membership and admission
Registration: Please pre-register by noon on 1/22 using the PayPal link at
http://www.svlifescience.com. Registrations received after the deadline will be applied to
next month's event, unless you've registered for the $100 ongoing or the $40-50 on-site
payment.
Audience: Entrepreneurs, intrapreneurs and investors, no service providers please.
Topic Description
Life Science Angel Investor's Panel: Trends for 2010
Life science angel investors are generally seasoned executives with deep strategic and
operational experience in running successful life science businesses, from concept to
clinical trials to regulatory approvals, manufacturing and distribution. They generally
also have extensive experience within corporations in various roles, and continue to
develop these partnerships as they support their portfolio companies.
The life science angel investors we've recruited for this month's panel have been seen a
wide range of life science business models, and have their own thoughts and
recommendations on how to be successful in these challenging times. Topics will include
how early stage companies can position themselves for successful partnerships and
fundings, strategically plan your business based on evolving market needs, tightly
manage cash flow, and build strategic alliances with larger organizations, angels,
research organizations, and other key stakeholders
In addition, this month, instead of profiling individual presenting entrepreneurs, we will
10
2/18/2016
break out into small groups, based on life science sub-industry topics: Software
solutions for the healthcare industry, medical devices, personalized medicine, medical
imaging, and biopharma.
Speaker Bios
Facilitator Conor Moore, Partner, KPMG
Conor Moore is KPMG's partner in charge of our Venture-Backed Practice in Northern
California and specialize in working with software, internet and biotechnology
companies. Prior to that, he was an audit manager at Arthur Andersen.
Mr. Moore earned his degree from University College Dublin with a B. Comm Accounting
and graduated from Blackrock College.
Panelist Anne DeGheest, Founder and Managing Director, MedStars, Strategic
Advisor at PolyRemedy, Inc
Anne DeGheest founded MedStars in 1986 and specializes in Medical Devices,
Services and Healthcare Information Systems. She has held leadership positions
in starting or building new Life Science companies with a cumulative market cap today
over $6 Billion, including Aspect Medical (Nasdaq: ASPM), ProDuct (acquired in 2001 by
Cytyc Corporation), Visicu (acquired in 2008 by Philips) and VISX (acquired in 2005 by
AMO). Anne serves on the board of directors of Immersion Corporation (Nasdaq: IMMR)
and is the founding investor and board member of Pixel Optics. She is on the device
screening committee of the Life Science Angels. She was an early investor and key
advisor to Thermage (Nasdaq: THRM) and Masimo (Nasdaq: MASI). She was the CEO of
medpool.com that she founded while an entrepreneur in residence with Institutional
Venture Partners. She was also involved in the successful startup of three well-known
medical companies. Anne was the founding Vice President of Marketing at Omnicell
Technologies (Nasdaq: OMCL), a market leader in automated point-of-use management
systems for medical supplies. Anne was instrumental in the turnaround of Pyxis, which
created and then dominated a new market segment in automated hospital drug
dispensing. Cardinal Healthcare purchased Pyxis in 1996. As a marketing director for
Nellcor, Anne started the pulse oximetry revolution. Nellcor went public and then was
sold to Malinckrodt in 1996. She held sales and marketing management positions at
Raychem where she was instrumental in starting a new division in the computer and
telecommunication industry. She has a Master in Commercial Engineering from the
University of Brussels, Belgium and a Master in Business Administration from Harvard.
Don Ross, Member, Life Science Angels and Sand Hill Angels
Mr. Ross has been active in life sciences for 25 years and co-founded a life
sciences publishing company that was acquired in 2000. He published
periodicals sponsored by major pharmaceutical companies in areas such as
allergy and asthma, skin care, psychopharmacology, and kidney health. In the
early 1980s, Mr. Ross developed software systems for psychological testing and
software applications for automated blood pressure monitoring at the work site.
Mr. Ross is co-author of two college-level nutrition textbooks, now in their second and
third editions. Originally trained as an architect, Mr. Ross graduated from UC Berkeley
with honors. He is an active investor in startup companies and assists with strategic
planning and business plan development. His investment focus is biomedical and
technology, and includes companies involved in therapeutic drug monitoring and medical
connectors.
Panelist Michael Weickert, President and CEO, S.E.A. Medical Systems, Inc., Member,
Life Science Angels, Venture Partner, Kranenburg Fund
Dr. Weickert is currently President and CEO of S.E.A. Medical Systems, Inc., a medical
11
2/18/2016
device startup developing the Smart IV. He advises Lypro Biosciences and
nanoBioSciences, serves on Screening Committees for Life Science Angels and is a
Venture Partner with Kranenburg Fund. Prior to S.E.A. Medical Dr. Weickert was Chief
Business Officer at Corium International, Inc., and StrataGent Life Sciences, Inc. He
managed marketing, business development, and finance and helped execute the merger
of both companies in a $40M transaction. He also held senior product development and
marketing positions at Auspex, Ligand, Somatogen, and Nektar.
**********************************************************************
***********
12
2/18/2016